Valeant Pharmaceuticals Intl Inc.: 3 Lessons From Bill Ackman’s Painful Experience

Bill Ackman has made mistakes with Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) that the rest of us can learn from.

| More on:
The Motley Fool

As Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) shares continue to plunge, activist investor Bill Ackman of Pershing Square Capital Management continues to stick by the company. He’s even bought more shares along the way, costing Pershing’s clients a ton of money.

To be fair to Mr. Ackman, he is still a widely respected investor, and for good reason. He has had a number of big successes, including the turnaround at Canadian Pacific Railway Limited, which has been a big win for shareholders of that company.

But much of his suffering with Valeant was avoidable, and there are some very valuable lessons we can all learn along the way.

1. Don’t hesitate to put stocks in the “too hardpile

Valeant has always been a difficult stock to analyze for a number of reasons. First of all, the company has been a serial acquirer for years, which makes it difficult to compare different time periods. On top of that, Valeant emphasizes non-GAAP measures in its financial reporting, such as “cash earnings per share,” which exclude some very legitimate costs. And if that wasn’t enough, sales data for individual drugs isn’t always provided.

Then when skeptics such as Andrew Left, Robby Boyd, and John Hempton started exposing Valeant’s seedy underbelly, the story got even more complicated. At this point, knowing what was going on at Valeant became impossible to figure out. And the company’s future became even more unclear.

At this point, Valeant deserved a place on the “too hard” pile, meaning the stock was too complicated to figure out, and thus too complicated to own. There’s nothing wrong with thinking this way, and anyone who did would have saved a lot of money on this stock, including Mr. Ackman.

2. Don’t be too concentrated

Most fund managers keep too many holdings in their portfolios, meaning they end up owning low-conviction ideas. But Mr. Ackman only has eight long holdings, meaning that any mistakes have a big impact on overall returns.

For an individual investor, this isn’t always such a big deal. But in Mr. Ackman’s case, when a stock moves against him, Wall Street starts speculating that he’ll have to reverse his bets to deal with fund redemptions or margin calls. This causes his positions to move further in the wrong direction.

For example, we’ve seen Herbalife Ltd. shares increase throughout this whole saga, feeding a vicious cycle for Mr. Ackman. This wouldn’t have happened if he were properly diversified.

3. Admit your mistakes

Admitting mistakes is never an easy thing to do, especially while investing. In Mr. Ackman’s case, it may be even harder simply because he has had so much success in the past.

We’ve seen other successful investors unable to admit mistakes. Bill Miller clung to financial stocks as the financial crisis unfolded. Eric Sprott stuck too much to junior mining companies. Like Mr. Ackman, both of these people may have been a victim of their past success.

As for the rest of us, when a stock moves in a big way against us, we must re-evaluate our position. And that means asking a very simple question: “If I didn’t already own the stock, would I buy it?” If the answer is no, then it’s time to sell.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned.  Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Nuclear power station cooling tower
Energy Stocks

Why Shares of Cameco Are Powering Higher

Cameco (TSX:CCO) shares have surged more than 400% in the last five years alone, with more growth on the way.

Read more »

A bull outlined against a field
Stocks for Beginners

Bull Market Buys: 2 TSX Stocks to Own for the Long Run

Are you looking for stocks that could see a bull run for decades ahead? Here are two top TSX stocks…

Read more »

financial freedom sign
Dividend Stocks

Million-Dollar TFSA: 1 Way to Achieve to 7-Figure Wealth

Achieving seven-figure TFSA wealth is doable with two large-cap, high-yield dividend stocks.

Read more »

analyze data
Dividend Stocks

How Much Will Manulife Financial Pay in Dividends This Year?

Manulife stock's dividend should be safe and the stock appears to be fairly valued.

Read more »

food restaurants
Dividend Stocks

Better Stock to Buy Now: Tim Hortons or Starbucks?

Starbucks and Restaurant Brands International are two blue-chip dividend stocks that trade at a discount to consensus price targets.

Read more »

Diggers and trucks in a coal mine
Metals and Mining Stocks

1 Canadian Mining Stock Worth a Long-Term Investment

Cameco (TSX:CCO) stock could be a great long-term investment for Canadian growth seekers.

Read more »

Pot stocks are a riskier investment
Investing

Could Investing $10,000 in Aurora Cannabis Stock Make You a Millionaire?

Let's dive into whether Aurora Cannabis (TSX:ACB) could be a potential millionaire-maker stock, or a dud, over the long term.

Read more »

stock analysis
Energy Stocks

Is Enbridge Stock a Good Buy in May 2024?

Boasting high-yielding dividends and a stable underlying business, Enbridge (TSX:ENB) might be a great buy for your self-directed investment portfolio…

Read more »